Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2014


Pain Therapeutics

19 May 2014 - 20 May 2014 - London, UK



Bookmark and Share


Assess Alternative Approaches to Animal Models to Minimise the Translational Gap and Accelerate Market Access

Pain Therapeutics 2014 will evaluate the latest regulatory guidelines on pain indications and assess the pricing and reimbursement issues which are faced with generic incursion and patent expiration.

Hear an in-depth analysis of new pain therapeutic targets from bench to bedside and assess the pipeline of novel drugs for unique insights into developments that could restore positive growth in the market.

REASONS TO ATTEND:

  • Discuss and evaluate the latest new therapeutic mechanisms from bench to bedside with key insight from Merck, Spinifiex, Eli Lilly, AbbVie and UCB
  • Hear key presentations from Mundipharma, Nektar and on advances to opioids and strategies to reduce abuse potential
  • Explore the latest in the area of Neuropathic pain for 2014 with the latest case studies from Neuroscience Technologies and GW Pharmaceuticals
  • Evaluate the translation gap with case studies from a pre-clinical and clinical perspective from Karolinska Institutet and OGB Consulting

KEY SPEAKERS:

  • Jordi Serra, CSO, Neuroscience Technologies Ltd
  • Samer Eid, Neuroscience Scientific Knowledge, Merck & Co.
  • Tom McCarthy, Chief Executive Officer and Managing Director, Spinifex Pharmaceuticals
  • Kathleen Kelly, Medical Leader, CNS/Pain, Johnson & Johnson
  • Zara Sands, Computational Medicinal Chemist, UCB
  • Birgit Priest, Senior Scientist, Eli Lilly
  • Philip Kym, Associate Director II, Pain Discovery Research, Abbott Laboratories

Pain Therapeutics has been a premier conference in its field for more than a decade and the 14th instalment will bring together even more key industry experts and leading pioneers to discuss, debate and share ideas and challenges facing the pain management arena. 

Visit http://www.smi-online.co.uk/goto/2014pain-therapeutics3.asp

Alternatively contact John Collins on +44 (0)20 7827 6734 or email jcollins@smi-online.co.uk 




Further information
Scientific News
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!